Zentalis Pharmaceuticals, Inc.
ZNTL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $67 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $67 | $0 | $0 | $0 |
| % Margin | 100% | – | – | – |
| R&D Expenses | $168 | $235 | $173 | $176 |
| G&A Expenses | $87 | $59 | $55 | $41 |
| SG&A Expenses | $87 | $59 | $55 | $41 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | $5 | $0 | $0 |
| Operating Expenses | $259 | $300 | $227 | $217 |
| Operating Income | -$191 | -$300 | -$227 | -$217 |
| % Margin | -283.6% | – | – | – |
| Other Income/Exp. Net | $26 | $7 | -$10 | $50 |
| Pre-Tax Income | -$166 | -$293 | -$238 | -$166 |
| Tax Expense | $0 | -$1 | -$0 | -$0 |
| Net Income | -$166 | -$292 | -$237 | -$159 |
| % Margin | -246% | – | – | – |
| EPS | -2.33 | -4.47 | -4.48 | -3.72 |
| % Growth | 47.9% | 0.2% | -20.4% | – |
| EPS Diluted | -2.33 | -4.47 | -4.48 | -3.72 |
| Weighted Avg Shares Out | 71 | 65 | 53 | 43 |
| Weighted Avg Shares Out Dil | 71 | 65 | 53 | 43 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $3 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$186 | -$248 | -$226 | -$207 |
| % Margin | -276.1% | – | – | – |